search
Back to results

Effect of a Low- Fermentable-Oligo-Di- Monosaccharides and Polyols Diet Group Intervention on IBS Symptoms and Fatigue (FODMAPS)

Primary Purpose

Irritable Bowel Syndrome

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Low- FODMAPdiet group intervention
Sponsored by
Karolinska Institutet
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Irritable Bowel Syndrome focused on measuring Low FODMAPdiet

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Established IBS-D by RomeIV- criteria
  • Established IBS-M by RomeIV- criteria
  • Body Mass Index (BMI)18-35

Exclusion criteria:

  • Pregnancy
  • Lactation
  • Ongoing eating disorder/ contact with eating disorder unit
  • Postoperative gastrointestinal surgery that may impact on the gastrointestinal function
  • Celiac disease
  • Psychiatric disorder
  • Other disorder that may impact the possibility to participate in group treatment
  • Diabetes
  • Ongoing low- FODMAPdiet treatment.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Low-FODMAPdiet group

    Delayed start of treatment low-FODMAPdiet group

    Arm Description

    Low-FODMAPdiet intervention as group treatment in three steps during 12 weeks, elimination, re-introduction and personalization of the diet. This group of participants starts immediate.

    Delayed start of treatment. This arm starts after three months

    Outcomes

    Primary Outcome Measures

    Change in IBS Symptom Severity Scores (IBS-SSS)
    Visual Analogues Scale (VAS-scale), composite score measuring bloating, bowel habits, satisfaction with with bowel habits and how IBS impact on QOL. Minimum score 0 and maximum score 500, higher scores indicates more severe disease

    Secondary Outcome Measures

    Change in Multidimensional Fatigue Inventory (MFI-20)
    The Multidimensional Fatigue Inventory-20 (MFI-20) assesses 5 dimensions of fatigue, the severity of general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. Each dimension contain 4 questions. In total 20 questions. Minimum score 0 and maximum score 100. A higher score indicate more severe fatigue.
    Change in the gastrointestinal symptom rating scale (GSRS-IBS)
    Measuring gastrointestinal symptom severity. Contains 13 questions. Minimum score 13 and maximum score 91. Higher score indicate more severe gastrointestinal symptoms.
    Change in Visceral sensitivity index (VSI)
    The VSI questionnaire measures GI-specific anxiety, and it includes the cognitive, affective, and behavioral response to fear of GI symptoms, and the context in which these occurs. The questionnaire contains 15 questions. Minimum score 0 and maximum score 75. A higher score indicates a more severe gastrointestinal anxiety.
    Change in Sickness behaviour (SQ)
    Measuring symptoms that occur after acute or chronic inflammation/ infection ie. malaise, listlessness, inability to concentrate, depressed mood and lack of interest in food and surroundings. The form contains 10 questions. Minimum score 0 and maximum score 30. Higher score indicates more severe sickness behaviour.
    Change in World Health Organisation (WHO) Disability Assessment Schedule (WHODAS 2.0)
    Measuring difficulties due to state of health. 12 questions. Minimum score is 12 and maximum score is 48. Higher score indicates more severe difficulties due to state.

    Full Information

    First Posted
    October 26, 2021
    Last Updated
    July 6, 2022
    Sponsor
    Karolinska Institutet
    Collaborators
    Aleris Gastromottagningen City
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05124262
    Brief Title
    Effect of a Low- Fermentable-Oligo-Di- Monosaccharides and Polyols Diet Group Intervention on IBS Symptoms and Fatigue
    Acronym
    FODMAPS
    Official Title
    Effect of a Low- Fermentable-Oligo-Di-Monosaccharides and Polyols (FODMAPs) Diet Group Intervention on IBS Symptoms and Fatigue
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    January 1, 2023 (Anticipated)
    Primary Completion Date
    March 15, 2024 (Anticipated)
    Study Completion Date
    March 15, 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Karolinska Institutet
    Collaborators
    Aleris Gastromottagningen City

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Irritable bowel disease (IBS) is a functional gastrointestinal disorder that affects 10% of the population. Comorbidities are common and fatigue is the most common extraintestinal complaint in IBS patients. There are no cure for the disease but there are nutrition treatments that can relieve symptoms. The main goal of this randomized controlled trial is to test the hypothesis that low-Fermentable- oligo-di- monosaccharides and polyols (FODMAPs) diet kan decrease gastrointestinal symptoms and improve quality of life and fatigue in patients with IBS.
    Detailed Description
    Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by stomach pain at least one day a week accompanied by change in stool frequency or appearance. Prevalence of IBS is about 10 % of the population worldwide and more common in women. IBS is divided into different subclasses: diarrhea predominant, (IBS-D), predominant constipation, (IBS-C), mixed bowel habits, (IBS-M). Comorbidities are common and fatigue is the most common extraintestinal complaint among the patients. Patients has severely reduced quality of life, reduced work capacity and the cost are substantial for the patients and the society. IBS can´t be cured but the symptoms can be relieved by pharmacological as well as non-pharmacological treatment as psychological- and nutritional treatment. The main goal of this randomized controlled trial is to test the hypothesis that low FODMAPdiet kan decrease gastrointestinal symptoms and improve quality of life and fatigue in patients with IBS. FODMAPs is an acronym for Fermentable-Oligo-Di-Monosaccharides and Polyols. FODMAPs are carbohydrates that can't be absorbed/splinted in the large intestine and they ferment rapidly and exacerbate gastrointestinal symptoms as flatulence, pain, bloating and loose stools. In total 120 patients with IBS-D and IBS-M will be randomized to immediate treatment start or delayed treatment start. The treatment will be performed in clinical setting, led by a dietitian and in group format including 12 patients in each group. The intervention time is 12 weeks with 5 group visits at a gastroenterology unit. The low-FODMAP treatment is divided into three steps: elimination of FODMAPs, re-introduction and personalization of the diet. Compliance to the diet will be measured by monitoring the FODMAP intake from three day food diaries and a compliance form. Questionnaires will be self reported in a web based application. Food diaries and the stomach diary will be filled out at baseline, at week 5, 12 and 6, 12 and 24 months post intervention.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Irritable Bowel Syndrome
    Keywords
    Low FODMAPdiet

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Sequential Assignment
    Model Description
    Randomized controlled trial with direct or delayed treatment start
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    120 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Low-FODMAPdiet group
    Arm Type
    Experimental
    Arm Description
    Low-FODMAPdiet intervention as group treatment in three steps during 12 weeks, elimination, re-introduction and personalization of the diet. This group of participants starts immediate.
    Arm Title
    Delayed start of treatment low-FODMAPdiet group
    Arm Type
    Experimental
    Arm Description
    Delayed start of treatment. This arm starts after three months
    Intervention Type
    Other
    Intervention Name(s)
    Low- FODMAPdiet group intervention
    Intervention Description
    Diet intervention
    Primary Outcome Measure Information:
    Title
    Change in IBS Symptom Severity Scores (IBS-SSS)
    Description
    Visual Analogues Scale (VAS-scale), composite score measuring bloating, bowel habits, satisfaction with with bowel habits and how IBS impact on QOL. Minimum score 0 and maximum score 500, higher scores indicates more severe disease
    Time Frame
    Change in baseline week 0 and after elimination at week 5, after intervention at week 12, at week 38 and at 1 year and 3 months and 2 years and three months. Within each patient.
    Secondary Outcome Measure Information:
    Title
    Change in Multidimensional Fatigue Inventory (MFI-20)
    Description
    The Multidimensional Fatigue Inventory-20 (MFI-20) assesses 5 dimensions of fatigue, the severity of general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. Each dimension contain 4 questions. In total 20 questions. Minimum score 0 and maximum score 100. A higher score indicate more severe fatigue.
    Time Frame
    Between baseline week 0 and after elimination at week 5, after intervention at week 12, at week 38 and at 1 year and 3 months and at 2 years and three months. Within each patient.
    Title
    Change in the gastrointestinal symptom rating scale (GSRS-IBS)
    Description
    Measuring gastrointestinal symptom severity. Contains 13 questions. Minimum score 13 and maximum score 91. Higher score indicate more severe gastrointestinal symptoms.
    Time Frame
    Between baseline week 0 and after elimination at week 5, after intervention at week 12, at week 38 and at 1 year and 3 months and at 2 years and three months. Within each patient.
    Title
    Change in Visceral sensitivity index (VSI)
    Description
    The VSI questionnaire measures GI-specific anxiety, and it includes the cognitive, affective, and behavioral response to fear of GI symptoms, and the context in which these occurs. The questionnaire contains 15 questions. Minimum score 0 and maximum score 75. A higher score indicates a more severe gastrointestinal anxiety.
    Time Frame
    Baseline week 0 and after intervention at 12 weeks and at week 38 and at 1 year and 3 months and 2 years and three months. Within each patient.
    Title
    Change in Sickness behaviour (SQ)
    Description
    Measuring symptoms that occur after acute or chronic inflammation/ infection ie. malaise, listlessness, inability to concentrate, depressed mood and lack of interest in food and surroundings. The form contains 10 questions. Minimum score 0 and maximum score 30. Higher score indicates more severe sickness behaviour.
    Time Frame
    Baseline week 0 after intervention at 12 weeks and at week 38, at 1 year and 3 months and 2 years and three months. Within each patient.
    Title
    Change in World Health Organisation (WHO) Disability Assessment Schedule (WHODAS 2.0)
    Description
    Measuring difficulties due to state of health. 12 questions. Minimum score is 12 and maximum score is 48. Higher score indicates more severe difficulties due to state.
    Time Frame
    Baseline week 0 and at 12 weeks and at week 38, at 1 year and 3 months and 2 years and three months. Within each patient.
    Other Pre-specified Outcome Measures:
    Title
    Change in three day food diary measuring FODMAPintake for compliance to diet intervention
    Description
    Patient report food intake during three days. Two weekdays and one saturday or sunday.
    Time Frame
    Baseline week 0, after intervention at 12 weeks and at 38 weeks, at 1 year and three months at 2 years and three months.. Within each patient.
    Title
    Change in meal pattern stomach diary 7 days,
    Description
    Measuring meal pattern
    Time Frame
    Baseline week 0, after intervention at 12 weeks and at 38 weeks, at 1 year and three months and at 2 years and three months. Within each patient.
    Title
    Change in stool pattern stomach diary 7 days
    Description
    Measuring stool pattern
    Time Frame
    Baseline week 0, after intervention at 12 weeks and at 38 weeks, at 1 year and three months and at 2 years and three months. Within each patient.
    Title
    Change in compliance to FODMAP intervention and level of introduction of FODMAPs
    Description
    Patients selfreport if they have reintroduced the different FODMAPs ie. fructose, lactose, fructan, galactooligosaccharides and polyols.
    Time Frame
    Postintervention at 12 weeks and at 38 weeks, 1 year and three months and at 2 years and three months. Within each patient.
    Title
    Change in Generalized Anxiety disorder (GAD-7)
    Description
    Measuring anxiety in total 7 questions added with questions about how the anxiety impacts your life. Minimum score 7 and maximum score 28. Higher score indicate more severe anxiety.
    Time Frame
    Baseline week 0 and after 1 year and three months. Within each patient.
    Title
    Change in Patients Health questionnaire (PHQ-9)
    Description
    Screening for depressive symptoms. 9 questions. Minimum score 0 and maximum score 27.
    Time Frame
    Baseline week 0 and at 1 year and three months. Within each patient.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion criteria: Established IBS-D by RomeIV- criteria Established IBS-M by RomeIV- criteria Body Mass Index (BMI)18-35 Exclusion criteria: Pregnancy Lactation Ongoing eating disorder/ contact with eating disorder unit Postoperative gastrointestinal surgery that may impact on the gastrointestinal function Celiac disease Psychiatric disorder Other disorder that may impact the possibility to participate in group treatment Diabetes Ongoing low- FODMAPdiet treatment.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    PerJohan Lindfors, MD, Med. dr
    Phone
    08-128 570 00
    Email
    perjohan.lindfors@ki.se
    First Name & Middle Initial & Last Name or Official Title & Degree
    Therese Liljebo, PHD- student
    Phone
    08-128 570 00
    Email
    therese.liljebo@ki.se
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    PerJohan Lindfors, MD, Med. dr
    Organizational Affiliation
    Karolinska Institutet
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Effect of a Low- Fermentable-Oligo-Di- Monosaccharides and Polyols Diet Group Intervention on IBS Symptoms and Fatigue

    We'll reach out to this number within 24 hrs